Vilnius, Lithuania and Neu-Isenburg, Germany – September 19th, 2025 – FarmaMondo Group and Kedrion Biopharma, a global leader in plasma-derived medicines, through its UK subsidiary, today announced an exclusive agreement to distribute Coagadex® (human coagulation factor X) across Estonia, Latvia, and Lithuania.
The agreement combines FarmaMondo’s expertise in market access and commercial distribution across emerging and complex markets with Kedrion’s long-standing leadership in developing and supplying plasma-derived therapies for rare diseases, including hemophilia and immunodeficiencies, as well as for ultra-rare conditions.
Coagadex® is the first and only treatment specifically indicated for hereditary factor X deficiency, an ultra-rare and potentially life-threatening bleeding disorder. By expanding access in the Baltics, this partnership will bring this therapy to patients who historically have had limited treatment options.
“This agreement reflects FarmaMondo’s mission to ensure patients with rare diseases gain timely access to innovative therapies,” said Yaron Spigel, Group CEO of FarmaMondo. “Together with Kedrion, we are proud to make this product available in the Baltics, filling a critical treatment gap for patients and their families.”
“At Kedrion, our focus has always been to deliver plasma-derived therapies that transform lives,” said Ferdinando Borgese VP, Commercial Director Intercontinental, Toll Fractionation & ICM Director, Kedrion. “Partnering with FarmaMondo allows us to make the treatment available to more patients in the Baltics who will benefit from this therapy for hereditary factor X deficiency.”
The collaboration underscores the commitment of both companies to advancing treatment options in rare diseases, strengthening their global partnership, and driving positive outcomes for patients and healthcare providers in the Baltics.
About Farma Mondo Group
FarmaMondo is a Swiss-based global commercialization partner specializing in rare, specialty, and orphan therapies. With 14 affiliates across Latin America, Asia Pacific, India & South Asia, MENA & Turkey, Russia & CIS, and select European countries, FarmaMondo accelerates patient access and creates new revenue opportunities in emerging markets. Trusted by leading biopharma companies, FarmaMondo combines centralized Swiss governance with deep local expertise to deliver life-changing medicines to more patients, faster.
For more details, please visit https://farmamondo.com/
About Kedrion Biopharma
Kedrion Biopharma collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions like coagulation and neurological disorders, immunodeficiencies, and Rh sensitization. We employ approximately 5,200 people worldwide and operate 68 plasma collection centers in the US and 8 in the Czech Republic. With a portfolio of 38 products distributed in over 100 countries, we are the world’s fifth largest player in plasma-derived products. We are committed to creating a world where science and care know no bounds, partnering with the medical-scientific community, institutions, patient advocacy groups, and research bodies to foster innovation and improve care. Every connection we make impacts someone, somewhere.
For more details, please visit kedrion.com
